Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.20%1.01B | 58.97%289M | -3.93%203.1M | 7.93%254.5M | 3.04%261.2M | 8.52%882.5M | -17.14%181.8M | -8.72%211.4M | 7.82%235.8M | 76.66%253.5M |
Operating revenue | 14.20%1.01B | 58.97%289M | -3.93%203.1M | 7.93%254.5M | 3.04%261.2M | 8.52%882.5M | -17.14%181.8M | -8.72%211.4M | 7.82%235.8M | 76.66%253.5M |
Cost of revenue | 109.01%719.2M | 184.01%243.4M | 75.72%146.9M | 96.72%174.1M | 33.49%116.8M | -16.22%344.1M | -13.17%85.7M | -25.49%83.6M | -23.84%88.5M | 4.67%87.5M |
Gross profit | -46.40%288.6M | -52.55%45.6M | -56.03%56.2M | -45.42%80.4M | -13.01%144.4M | 33.76%538.4M | -20.38%96.1M | 7.04%127.8M | 43.71%147.3M | 177.13%166M |
Operating expense | 93.04%133.2M | 84.41%34.3M | 182.07%40.9M | -8.60%17M | 136.99%41M | 16.75%69M | 16.98%18.6M | -8.81%14.5M | 27.40%18.6M | 36.22%17.3M |
Selling and administrative expenses | 100.63%126.8M | 96.89%31.7M | 200.76%39.7M | -11.93%15.5M | 144.79%39.9M | 14.49%63.2M | 10.27%16.1M | -12.00%13.2M | 27.54%17.6M | 38.14%16.3M |
Research and development costs | 10.34%6.4M | 4.00%2.6M | -7.69%1.2M | 50.00%1.5M | 10.00%1.1M | 48.72%5.8M | 92.31%2.5M | 44.44%1.3M | 25.00%1M | 11.11%1M |
Operating profit | -66.89%155.4M | -85.42%11.3M | -86.50%15.3M | -50.74%63.4M | -30.46%103.4M | 36.69%469.4M | -26.05%77.5M | 9.47%113.3M | 46.42%128.7M | 215.04%148.7M |
Net non-operating interest income expense | 20.3M | 1.5M | -1.5M | 9.3M | 11M | 0 | 0 | 0 | 0 | 0 |
Non-operating interest income | --20.3M | ---- | ---- | --9.3M | --11M | --0 | ---- | ---- | --0 | --0 |
Total other finance cost | ---- | ---- | --1.5M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other net income (expense) | 143.41%34.9M | 110.45%3M | -35.54%-22.5M | 338.91%57.1M | -307.00%-40.7M | -905.00%-80.4M | -72.89%-28.7M | -277.27%-16.6M | -1,139.13%-23.9M | -193.46%-10M |
Gain on sale of security | ---- | ---- | 3,833.33%44.8M | 951.32%79.9M | ---- | ---- | ---- | ---1.2M | --7.6M | ---- |
Earnings from equity interest | 67.53%-7.5M | -45.45%-1.6M | 11.94%-5.9M | --0 | --0 | -52.98%-23.1M | 83.58%-1.1M | -91.43%-6.7M | -166.67%-7.2M | -268.18%-8.1M |
Special income (charges) | -269.07%-210M | -109.13%-45.8M | -605.75%-61.4M | 6.17%-22.8M | -4,310.53%-83.8M | -602.47%-56.9M | -655.17%-21.9M | -866.67%-8.7M | -659.38%-24.3M | -72.73%-1.9M |
-Less:Restructuring and merger&acquisition | 164.15%150.3M | 64.86%36.6M | -5.88%12.8M | 17.95%23M | 4,300.00%83.6M | 611.25%56.9M | 416.28%22.2M | 2,166.67%13.6M | 680.00%19.5M | 216.67%1.9M |
-Less:Impairment of capital assets | --58.6M | --6.9M | --51.7M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
-Less:Other special charges | --1.1M | --2.3M | 36.73%-3.1M | -104.17%-200K | --200K | ---- | ---- | -1,733.33%-4.9M | 585.71%4.8M | ---- |
Other non- operating income (expenses) | 63,200.00%252.4M | ---- | ---- | ---- | --43.1M | -102.63%-400K | ---- | ---- | ---- | ---- |
Income before tax | -45.86%210.6M | -67.62%15.8M | -109.00%-8.7M | 23.85%129.8M | -46.86%73.7M | 15.98%389M | -44.67%48.8M | -2.42%96.7M | 16.19%104.8M | 139.55%138.7M |
Income tax | 33.96%78.9M | 109.01%23.2M | -459.14%-33.4M | 141.78%35.3M | 125.10%53.8M | -4.85%58.9M | 101.82%11.1M | -56.74%9.3M | -51.66%14.6M | 408.51%23.9M |
Net income | -60.10%131.7M | -119.63%-7.4M | -71.74%24.7M | 4.77%94.5M | -82.67%19.9M | 20.69%330.1M | -54.41%37.7M | 12.63%87.4M | 50.33%90.2M | 115.79%114.8M |
Net income continuous Operations | -60.10%131.7M | -119.63%-7.4M | -71.74%24.7M | 4.77%94.5M | -82.67%19.9M | 20.69%330.1M | -54.41%37.7M | 12.63%87.4M | 50.33%90.2M | 115.79%114.8M |
Minority interest income | 28.5M | 6.8M | 8.6M | 8.8M | 4.3M | 0 | 0 | 0 | 0 | 0 |
Net income attributable to the parent company | -68.74%103.2M | -137.67%-14.2M | -81.58%16.1M | -4.99%85.7M | -86.41%15.6M | 20.69%330.1M | -54.41%37.7M | 12.63%87.4M | 50.33%90.2M | 115.79%114.8M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -68.74%103.2M | -137.67%-14.2M | -81.58%16.1M | -4.99%85.7M | -86.41%15.6M | 20.69%330.1M | -54.41%37.7M | 12.63%87.4M | 50.33%90.2M | 115.79%114.8M |
Basic earnings per share | -86.84%0.1 | -112.50%-0.01 | -95.00%0.01 | -61.90%0.08 | -96.30%0.01 | 15.15%0.76 | -58.16%0.08 | 11.91%0.2 | 40.35%0.21 | 96.85%0.27 |
Diluted earnings per share | -86.36%0.09 | -112.50%-0.01 | -94.12%0.01 | -61.11%0.07 | -95.65%0.01 | 17.86%0.66 | -50.65%0.08 | 10.55%0.17 | 39.70%0.18 | 97.64%0.23 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |